标题
Back to the future: oral targeted therapy for RA and other autoimmune diseases
作者
关键词
-
出版物
Nature Reviews Rheumatology
Volume 9, Issue 3, Pages 173-182
出版商
Springer Nature
发表日期
2013-02-19
DOI
10.1038/nrrheum.2013.7
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Sorafenib in hepatocellular carcinoma
- (2014) Debra H Josephs et al. BRITISH JOURNAL OF HOSPITAL MEDICINE
- JAKs and STATs in Immunity, Immunodeficiency, and Cancer
- (2013) John J. O'Shea et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year
- (2012) F. Vincenti et al. AMERICAN JOURNAL OF TRANSPLANTATION
- JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production
- (2012) Timothy P. LaBranche et al. ARTHRITIS AND RHEUMATISM
- JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
- (2012) A. Tefferi BLOOD
- Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
- (2012) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion
- (2012) Paul M. Barr et al. CLINICAL IMMUNOLOGY
- Novel small-molecular therapeutics for rheumatoid arthritis
- (2012) Roy Fleischmann CURRENT OPINION IN RHEUMATOLOGY
- PKCθ: a new target for selective immunosuppression
- (2012) Amnon Altman et al. Expert Review of Clinical Immunology
- JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
- (2012) John J. O'Shea et al. IMMUNITY
- Tec Family Kinases in Inflammation and Disease
- (2012) Nicole J. Horwood et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF- B Pathways
- (2012) X. Wu et al. MOLECULAR CANCER THERAPEUTICS
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protein Kinase C Inhibition Ameliorates Posttransplantation Preservation Injury in Rat Renal Transplants
- (2012) Tom Florian Fuller et al. TRANSPLANTATION
- A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
- (2011) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
- (2011) Roy Fleischmann et al. ARTHRITIS AND RHEUMATISM
- The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells
- (2011) Keisuke Maeshima et al. ARTHRITIS AND RHEUMATISM
- Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitors
- (2011) Alaric J. Dyckman et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Tec family kinases Itk and Rlk / Txk in T lymphocytes: cross-regulation of cytokine production and T-cell fates
- (2011) Julio Gomez-Rodriguez et al. FEBS Journal
- Tec family kinases: regulation of FcεRI-mediated mast-cell activation
- (2011) Wilfried Ellmeier et al. FEBS Journal
- Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
- (2011) Kamran Ghoreschi et al. JOURNAL OF IMMUNOLOGY
- Possible role of the JAK/STAT pathways in the regulation of T cell-interferon related genes in systemic lupus erythematosus
- (2011) M Kawasaki et al. LUPUS
- Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate
- (2011) Yoshiya Tanaka et al. ARTHRITIS CARE & RESEARCH
- Optimal case definitions of upper extremity disorder for use in the clinical treatment and referral of patients
- (2011) Keith T. Palmer et al. ARTHRITIS CARE & RESEARCH
- Consensus treatments for moderate juvenile dermatomyositis: Beyond the first two months. Results of the Second Childhood Arthritis and Rheumatology Research Alliance Consensus Conference
- (2011) Adam M. Huber et al. ARTHRITIS CARE & RESEARCH
- A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis
- (2011) Kristine L Stump et al. ARTHRITIS RESEARCH & THERAPY
- The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells
- (2011) Betty Y Chang et al. ARTHRITIS RESEARCH & THERAPY
- Intravenous immunoglobulin does not prevent recurrence of congenital heart block in children of SSA/Ro-positive mothers
- (2010) Monika ØStensen ARTHRITIS AND RHEUMATISM
- An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents
- (2010) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Kinase inhibitors: a new approach to rheumatoid arthritis treatment
- (2010) Stanley Cohen et al. CURRENT OPINION IN RHEUMATOLOGY
- Jak/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL/lpr mice
- (2010) S. Wang et al. LUPUS
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- T Cell Activation
- (2009) Jennifer E. Smith-Garvin et al. Annual Review of Immunology
- The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
- (2009) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2009) J. W. Friedberg et al. BLOOD
- The tyrosine kinase network regulating mast cell activation
- (2009) Alasdair M. Gilfillan et al. IMMUNOLOGICAL REVIEWS
- Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial
- (2008) Michael E. Weinblatt et al. ARTHRITIS AND RHEUMATISM
- An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus
- (2008) Frances Rena Bahjat et al. ARTHRITIS AND RHEUMATISM
- The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia
- (2008) Elizabeth Kudlacz et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started